VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ General good health as established by medical      │ General good health as established by medical      │     100 │
│ history and physical examination                   │ history and physical examination                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Written informed consent                           │ Written informed consent                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Females of childbearing potential must agree to    │ Females of childbearing potential must agree to    │     100 │
│ use an efficacious hormonal or barrier method of   │ use an efficacious hormonal or barrier method of   │         │
│ birth control during the study. Abstinence is      │ birth control during the study. Abstinence is      │         │
│ acceptable                                         │ acceptable                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Available for all visits scheduled in this study   │ Available for all visits scheduled in this study   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Primary groups: Vaccination against typhoid fever  │ Primary groups: Vaccination against typhoid fever  │     100 │
│ within 5 years before dosing                       │ within 5 years before dosing                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of clinical typhoid fever, clinical        │ History of clinical typhoid fever, clinical        │     100 │
│ paratyphoid A or B fever                           │ paratyphoid A or B fever                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Immunization with any other vaccine (oral or       │ Immunization with any other vaccine (oral or       │     100 │
│ parenteral) within 4 weeks prior to study start or │ parenteral) within 4 weeks prior to study start or │         │
│ planned vaccination during the study               │ planned vaccination during the study               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic (longer than 14 days) administration of    │ Chronic (longer than 14 days) administration of    │     100 │
│ immunosuppressants or other immune-modifying drugs │ immunosuppressants or other immune-modifying drugs │         │
│ within 6 months before the first dose of           │ within 6 months before the first dose of           │         │
│ investigational vaccine; oral corticosteroids in   │ investigational vaccine; oral corticosteroids in   │         │
│ dosages of ≥0.5 mg/kg/d prednisolone or equivalent │ dosages of =0.5 mg/kg/d prednisolone or equivalent │         │
│ are excluded; inhaled or topical steroids are      │ are excluded; inhaled or topical steroids are      │         │
│ allowed                                            │ allowed                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acute or chronic clinically significant            │ Acute or chronic clinically significant            │     100 │
│ gastrointestinal disease                           │ gastrointestinal disease                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male or female subjects aged ≥18 to ≤65 years      │ Male or female subjects aged =18 to =65 years      │      96 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current intake of antibiotics or end of antibiotic │ Current intake of antibiotics or end of antibiotic │      99 │
│ therapy \<8 days before first IMP administration   │ therapy <8 days before first IMP administration    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                 │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Male or female subjects aged =18 to =65 years │      46 │
├───────────────────────────────────┼───────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 64 Years │ Male or female subjects aged =18 to =65 years │      51 │
╘═══════════════════════════════════╧═══════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 91.6923076923077
OverAll Ratio: 94.34615384615384
